Kwality Pharmaceutical (KPL) has successfully received domestic and export product approvals for the manufacturing and sale of its biological product, PEGylated-Asparaginase. This significant milestone underscores the company’s commitment to delivering high-quality therapeutic solutions and marks an important step forward, as it is its first product from the biologics portfolio to be commercialized in both domestic and export markets.
L-Asparaginase is an E. coli-derived enzyme primarily used in the treatment of acute lymphoblastic leukemia (ALL). The PEGylation process enhances the stability of the molecule and reduces the risk of allergic reactions, thereby improving patient outcomes and treatment efficacy.
Furthermore, Kwality Pharmaceutical is actively engaged in discussions with leading domestic B2B companies to offer PEGylated-Asparaginase on a CDMO (Contract Development and Manufacturing Organization) basis. These collaborations aim to leverage its manufacturing expertise, ensuring wider availability of this critical therapy. This approach not only strengthens local partnerships but also enhances patient access across various regions.
Kwality Pharmaceuticals (formerly Kwality Pharmaceuticals) is a pharmaceutical formation company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1712.05 |
Dr. Reddys Lab | 1146.70 |
Cipla | 1450.05 |
Lupin | 2007.00 |
Zydus Lifesciences | 894.15 |
View more.. |